Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?

Abstract

Despite significant breakthroughs in understanding of immunological and physiological features of autoimmune diseases, there is currently no specific therapeutic option with prolonged remission. Cell-based therapy using engineered-T cells has attracted tremendous attention as a practical treatment for autoimmune diseases. Genetically modified-T cells armed with chimeric antigen receptors (CARs) attack autoreactive immune cells such as B cells or antibody-secreting plasma cells. CARs can further guide the effector and regulatory T cells (Tregs) to the autoimmune milieu to traffic, proliferate, and exert suppressive functions. The genetically modified-T cells with artificial receptors are a promising option to suppress autoimmune manifestation and autoinflammatory events. Interestingly, CAR-T cells are modified to a new chimeric auto-antibody receptor T (CAAR-T) cell. This cell, with its specific-antigen, recognizes and binds to the target autoantibodies expressing autoreactive cells and, subsequently, destroy them. Preclinical studies of CAR-T cells demonstrated satisfactory outcomes against autoimmune diseases. However, the lack of target autoantigens remains one of the pivotal problems in the field of CAR-T cells. CAR-based therapy has to pass several hurdles, including stability, durability, trafficking, safety, effectiveness, manufacturing, and persistence, to enter clinical use. The primary goal of this review was to shed light on CAR-T immunotherapy, CAAR-T cell therapy, and CAR-Treg cell therapy in patients with immune system diseases.

Fibroblast pathology in inflammatory joint disease

“…Furthermore, a phase I clinical trial has proven that local delivery of FAPα CAR T cells is safe in patients with pleural mesothelioma 191 . These findings are promising, prompting development of such therapeutic approaches in RA and other autoimmune diseases 192 …”

Infectious complications of CAR T-cell therapy: a clinical update

“… 6 – 10 CAR T-cell immunotherapies are also being developed for autoimmune diseases and viral infections. 11 , 12 In particular, CAR T-cell therapy has produced impressive outcomes in patients with relapsed or refractory (R/R) B-cell malignancies. The first CAR T-cell therapeutic tisagenlecleucel was given to 93 adult patients with R/R B-cell lymphoma in a phase II trial and demonstrated a 52% response rate overall.…”

EVA1C Is a Potential Prognostic Biomarker and Correlated With Immune Infiltration Levels in WHO Grade II/III Glioma

“…Immunotherapy has emerged as one of the most important therapeutic means for tumor in the past decades ( 7 , 8 ). Especially, approaches targeting recognized immune checkpoints, such as anti-PD-1 and anti-CTLA4, have been approved for clinical utilization and achieved encouraging outcomes ( 9 , 10 ). However, there are still some limitations in existing T cell-based immunotherapies, which are attributed to the extremely complex immunosuppressive processes of tumor microenvironment (TME) and its regulatory networks ( 11 ).…”